Nebivolol
Is It Right for You?
A complete guide to Nebivolol — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Nebivolol?
Nebivolol is a third-generation, highly selective beta-1 adrenoceptor blocker (beta-blocker) with a unique dual mechanism that distinguishes it from all other members of its drug class. Available in 5 mg tablets taken once daily, it is used primarily for the management of hypertension and, in older patients, stable heart failure.
What sets nebivolol apart from earlier beta-blockers is its additional vasodilatory action. Unlike conventional beta-blockers (which can cause peripheral vasoconstriction — a side effect responsible for cold extremities and worsened symptoms in peripheral arterial disease), nebivolol stimulates the release of nitric oxide (NO) from vascular endothelium, producing direct peripheral vasodilation. This results in a smoother reduction in blood pressure, improved peripheral circulation, and a significantly better tolerability profile — including a substantially lower incidence of sexual dysfunction compared to older beta-blockers.
Its exceptional selectivity for beta-1 receptors (with negligible activity at beta-2 receptors in the lungs) also makes it one of the safest beta-blockers for use in patients with mild-to-moderate obstructive lung disease, though caution is still required.
Nebivolol is a prescription-only medication in the UK.
What Conditions Is Nebivolol Used For?
Nebivolol is indicated for:
long-term treatment of high blood pressure in adults
as an adjunct to standard heart failure therapy in elderly patients (≥70 years) with reduced or preserved ejection fraction
Abrupt withdrawal of beta-blockers — particularly in patients with ischaemic heart disease — can precipitate a severe rebound effect causing angina, myocardial infarction, or dangerous arrhythmias. Always taper nebivolol gradually under medical supervision.
How Does Nebivolol Work?
Nebivolol lowers blood pressure and heart rate through two complementary mechanisms:
Selective beta-1 adrenoceptor blockade in the heart reduces the rate and force of cardiac contraction in response to sympathetic nervous system stimulation. This lowers heart rate (negative chronotropy), reduces myocardial contractility (negative inotropy), and decreases cardiac output — collectively reducing the work the heart must do and lowering blood pressure. Over time, beta-blockade also suppresses renin release from the kidneys, reducing angiotensin II production and further contributing to blood pressure reduction.
Nitric oxide-mediated vasodilation — nebivolol (specifically its D-nebivolol enantiomer) stimulates endothelial nitric oxide synthase (eNOS), increasing the production of nitric oxide in vascular endothelium. NO causes direct relaxation of vascular smooth muscle, producing peripheral vasodilation and lowering peripheral vascular resistance. This vasodilatory component counteracts the reflex peripheral vasoconstriction associated with classic beta-blockers, resulting in better peripheral blood flow and a more favourable haemodynamic profile.
The combination of cardiac rate/output reduction and peripheral vasodilation produces effective, well-tolerated blood pressure control.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Always follow your clinician's instructions. Take at the same time each day, with or without food. Consistency of timing supports stable plasma levels. Take in the morning unless your clinician advises otherwise — avoiding evening doseTake at the same time each day, with or without food. Consistency of timing supports stable plasma levels.
Take in the morning unless your clinician advises otherwise — avoiding evening doses reduces the risk of any nocturnal bradycardia-related symptoms.
Do not stop nebivolol suddenly. If discontinuation is required, the dose should be tapered gradually over 1–2 weeks, particularly in patients with coronary artery disease.
Monitor your heart rate. Contact your clinician if your resting heart rate regularly falls below 50–55 beats per minute, or if you experience symptoms of bradycardia (dizziness, fatigue, near-fainting).
s reduces the risk of any nocturnal bradycardia-related symptoms. Do not stop nebivolol suddenly. If discontinuation is required, the dose should be tapered gradually over 1–2 weeks, particularly in patients with coronary artery disease. Monitor your heart rate. Contact your clinician if your resting heart rate regularly falls below 50–55 beats per minute, or if you experience symptoms of bradycardia (dizziness, fatigue, near-fainting).
Side Effects of Nebivolol
Nebivolol is generally very well tolerated — with a lower incidence of the sexual dysfunction and cold extremities commonly associated with older beta-blockers, due to its vasodilatory properties.
- Headache
- Fatigue and asthenia
- Dizziness
- Bradycardia (slow heart rate)
- Cold hands and feet (less common than with older beta-blockers)
- Nausea
- Paraesthesia (tingling sensations)
- Dyspnoea (breathlessness) — particularly at higher doses
- Severe bradycardia / heart block — very slow heart rate, extreme fatigue, dizziness, loss of consciousness
- Acute heart failure decompensation — worsening of breathlessness, leg oedema, and fatigue during heart failure titration
- Bronchospasm — wheeze and breathlessness in susceptible patients with asthma or COPD; even highly selective beta-blockers carry some risk
- Severe hypotension — particularly at initiation in volume-depleted patients
- Peripheral ischaemia exacerbation — worsening of symptoms in severe peripheral arterial disease
Do not stop abruptly. Sudden discontinuation of nebivolol — particularly in patients with ischaemic heart disease — can precipitate unstable angina, myocardial infarction, or severe arrhythmia. Always taper gradually over at least 1–2 weeks under medical supervision.
Drug Interactions
Nebivolol may interact with other medications, including MAOIs, CNS depressants, and strong CYP2D6 inhibitors. Always inform your clinician about all medications you are taking.
Additive negative effects on heart rate and AV conduction; risk of severe bradycardia and complete heart block. IV verapamil is absolutely contraindicated with any beta-blocker.
If clonidine is to be discontinued in a patient also on a beta-blocker, the beta-blocker must be withdrawn first and several days allowed before stopping clonidine — to prevent a severe rebound hypertensive crisis.
Substantially increase nebivolol plasma concentrations; monitor for enhanced beta-blockade effects (bradycardia, hypotension).
Additive blood pressure lowering; monitor for excessive hypotension
Important Warnings
Sudden discontinuation of nebivolol — particularly in patients with ischaemic heart disease — can precipitate unstable angina, myocardial infarction, or severe arrhythmia. Always taper gradually over at least 1–2 weeks under medical supervision.
Nebivolol is contraindicated in patients with bronchial asthma or severe obstructive lung disease. Even highly selective beta-1 blockers retain the potential to provoke bronchospasm in susceptible individuals. Patients with mild-to-moderate COPD who require beta-blockade should be closely monitored and started at very low doses.
Nebivolol must not be used in patients with significant sinus bradycardia (heart rate <60 bpm at rest), greater than first-degree AV block (without a pacemaker), or sick sinus syndrome. Monitor heart rate regularly during treatment.
Beta-blockers blunt the tachycardia that typically alerts diabetic patients to hypoglycaemia. Patients with insulin-dependent diabetes should be warned and should monitor blood glucose more closely.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Nebivolol FAQs
Yes — nebivolol is a third-generation beta-blocker with a unique nitric oxide-mediated vasodilatory effect that distinguishes it from older agents such as atenolol and bisoprolol. This vasodilation contributes to better tolerability, including a lower incidence of cold extremities and sexual dysfunction.
No — nebivolol is contraindicated in asthma and severe obstructive lung disease. Even the most selective beta-1 blockers can trigger bronchospasm in people with asthma. An alternative antihypertensive class should be used.
Beta-blockers limit the maximum heart rate achievable during exercise. You may notice reduced exercise capacity and a blunted exercise heart rate response. This is a pharmacological effect, not a sign of something wrong, but discuss it with your clinician if it significantly affects your activity levels.
Nebivolol can be used in diabetes, but the masking of hypoglycaemia symptoms (particularly tachycardia) means more frequent blood glucose monitoring is required if you are on insulin or sulfonylureas. Sweating as a hypoglycaemia symptom remains unmasked.
If you feel persistently faint, exhausted, or unwell and notice a very slow pulse (below 50–55 bpm), contact your clinician promptly. Do not stop nebivolol abruptly — seek advice first.